新闻中心
>
Media Information
-
2021-01-06
Beijing Shenogen Pharma Group Ltd. Disclosed the New Findings Related to Icaritin treatment induced Immunomodulation in HCC Tumor Microenvironment
Recently, the internationally renowned European Journal of Immunology published …+阅读更多 -
2020-09-25
Cancer Science Online Publication: Phase II Data Demonstrated Clinical Safety and Efficacy of First-in-Class Small Molecule Icaritin in Patients with Advanced HBV-related Hepatocellular Carcinoma
Congratulations to team investigators and ShenogenPharma teams. Cancer Science…+阅读更多 -
2019-08-30
European Journal of Immunology (published online) New Evidence for Icaritin, a Small Molecule Discovered from a Chinese Herb by Beijing Shenogen Pharma Group, to Elicit Immunological Responses and Inhibit Tumor Growth
Recently, the renowned European Journal of Immunology published an article tit…+阅读更多 -
2019-04-12
icaritin phase IIA trial showed favorable safety profiles and preliminary durable survival benefits in advanced HCC patients in BMC Cancer online Publication
Icaritin early phase Trial: With poor prognosis and limitedtreatment options for…+阅读更多 -
2018-05-25
IDG-Backed Shenogen Said to Interview Banks for $300 Million IPO – Bloomberg
+阅读更多 -
2018-03-26
Reward and risk: the two faces of Hong Kong’s new listing rules for biotech firms
Reward and risk: the two faces of HongKong’s new listing rules for biotech firm…+阅读更多